Rowan University

Rowan Digital Works
Faculty Scholarship for the College of Science &
Mathematics

College of Science & Mathematics

9-7-2021

Characterization of gut microbiome and metabolome in
Helicobacter pylori patients in an underprivileged community in
the United States
Brian White
John D Sterrett
Zoya Grigoryan
Lauren Lally
Jared D Heinze

See next page for additional authors

Follow this and additional works at: https://rdw.rowan.edu/csm_facpub
Part of the Medicine and Health Sciences Commons

Recommended Citation
White, Brian; Sterrett, John D; Grigoryan, Zoya; Lally, Lauren; Heinze, Jared D; Alikhan, Hyder; Lowry,
Christopher A; Perez, Lark; DeSipio, Joshua; and Phadtare, Sangita, "Characterization of gut microbiome
and metabolome in Helicobacter pylori patients in an underprivileged community in the United States"
(2021). Faculty Scholarship for the College of Science & Mathematics. 222.
https://rdw.rowan.edu/csm_facpub/222

This Article is brought to you for free and open access by the College of Science & Mathematics at Rowan Digital
Works. It has been accepted for inclusion in Faculty Scholarship for the College of Science & Mathematics by an
authorized administrator of Rowan Digital Works.

Authors
Brian White, John D Sterrett, Zoya Grigoryan, Lauren Lally, Jared D Heinze, Hyder Alikhan, Christopher A
Lowry, Lark Perez, Joshua DeSipio, and Sangita Phadtare

This article is available at Rowan Digital Works: https://rdw.rowan.edu/csm_facpub/222

bioRxiv preprint doi: https://doi.org/10.1101/2021.05.23.445270; this version posted May 25, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Characterization of gut microbiome and metabolome in Helicobacter pylori patients
in an underprivileged community in the United States
Brian E. White*, John D. Sterrett*, Zoya Grigoryan*, Lauren T. Lally, Jared D. Heinze,
Hyder Alikhan, Christopher A. Lowry, Lark Perez, Joshua DeSipio, Sangita Phadtare
Brian White, BA, Sangita Phadtare, PhD, Department of Biomedical Sciences, Cooper
Medical School Rowan University, Camden, NJ, USA
John Sterrett, BS, Jared D. Heinze, MPH, Christopher A. Lowry, PhD, Department of
Integrative Physiology, University of Colorado Boulder, Boulder, CO, USA
Zoya Grigoryan, MD, Department of Internal Medicine, Lenox Hill Hospital, NYC, NY,
USA
Lauren T. Lally, MD, Department of Internal Medicine, Thomas Jefferson University
Hospital, Philadelphia, PA, USA
Hyder Alikhan, Department of Biological Sciences, Rowan University, Rowan
University, Glassboro, NJ, USA
Lark Perez, PhD, Department of Chemistry and Biochemistry, Rowan University,
Glassboro, NJ, USA
Joshua DeSipio, MD, Department of Gastroenterology, Cooper University Hospital,
Camden, NJ, USA
*: White, Sterrett and Grigoryan contributed equally to the work.
Corresponding author: Sangita Phadtare, PhD, Department of Biomedical Sciences,
Cooper Medical School Rowan University, Camden, NJ, USA. phadtare@rowan.edu

1

bioRxiv preprint doi: https://doi.org/10.1101/2021.05.23.445270; this version posted May 25, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

ABSTRACT
Background. Helicobacter pylori, a bacterium that infects approximately half of the
world’s population, is associated with various gastrointestinal diseases, including
peptic ulcers, non-ulcer dyspepsia, gastric adenocarcinoma, and gastric lymphoma. To
combat the increasing antibiotic resistance of H. pylori, the need for new therapeutic
strategies has become more pressing. Characterization of the interactions between H.
pylori and the fecal microbiome, as well as the mechanisms underlying these
interactions, may offer new therapeutic approaches. Exploration of changes in fatty acid
metabolism associated with H. pylori-mediated alterations of the fecal microbiome may
also reveal strategies to help prevent progression to neoplasia.
Aim. To characterize the gut microbiome and metabolome in H. pylori patients in a
socioeconomically challenged and underprivileged inner-city community.
Methods. Stool samples from 19 H. pylori patients and 16 control subjects were
analyzed. 16S rRNA gene sequencing was performed on normalized pooled amplicons
using the Illumina MiSeq System using a MiSeq reagent kit v2. Alpha and beta diversity
analyses were performed in QIIME 2. Non-targeted fatty acid analysis of the samples
was carried out using gas chromatography-mass spectrometry (GC-MS), which
measures the total content of 30 fatty acids in stool after conversion into their
corresponding fatty acid methyl esters. Multi-dimensional scaling (MDS) was
performed on Bray-Curtis distance matrices created from both the metabolomics and
microbiome datasets and a Procrustes test was performed on the metabolomics and
microbiome MDS coordinates.
Results. Fecal microbiome analysis showed that alpha diversity was lowest in H. pylori
patients over 40 years of age compared to control subjects of similar age group. Beta
diversity analysis of the samples revealed significant differences in microbial
community structure between H. pylori patients and control subjects. Thirty-eight and
six taxa had lower and higher relative abundance in H. pylori patients, respectively.
Taxa that were enriched in H. pylori patients included Atopobium, Gemellaceae,
Micrococcaceae, Gemellales and Rothia (R. mucilaginosa). Notably, relative abundance of
the phylum Verrucomicrobia was decreased in H. pylori patients compared to control
subjects, suggesting disruption of the gut mucosal environment by H. pylori. Procrustes
analysis showed a significant relationship between the microbiome and metabolome
datasets. Stool samples from H. pylori patients showed increases in several fatty acids
including the polyunsaturated fatty acids (PUFAs) 22:4n6, 22:5n3, 20:3n6 and 22:2n6,
while decreases were noted in other fatty acids including the PUFA 18:3n6. The pattern
of changes in fatty acid concentration correlated to the Bacteroidetes:Firmicutes ratio
determined by 16S rRNA gene analysis.
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Conclusion. An individualized understanding of gut microbiome features among H.
pylori patients will pave the way for improved community impact, reduced healthcare
burdens of repeated treatment, and decreased mounting resistance.
Key words: Gut microbiome; Metabolome; Helicobacter pylori; Antibiotic resistance;
Dysbiosis
Abbreviations
10-HOE, 10-hydroxy-cis-12-octadecenoic acid
DHA, docosahexaenoic acid, 22:6 (n-3)
DNL, de novo lipogenesis
FAME, fatty acid methyl ester
GC-MS, gas chromatography–mass spectrometry
IBD, inflammatory bowel disease
IRB, Institutional Review Board
LDA, Linear Discriminant Analysis
LEfSe, Linear Discriminant Analysis (LDA) Effect Size (LEfSe)
MDS, multidimensional scaling
MUFA, monounsaturated fatty acid
OTU, operational taxonomic unit
PCoA, principal coordinate analysis
PERMANOVA, permutational multivariate analysis of variance
PERMDISP, permutational analysis of multivariate dispersions
PPI, proton pump inhibitor
PROTEST, Procrustes randomization test
PUFA, polyunsaturated fatty acid
QC, quality control
QIIME, Quantitative Insights Into Microbial Ecology
SCFA, short-chain fatty acid
SIM, single ion monitoring
sOTU, sub-operational taxonomic unit
UniFrac, unique fraction metric
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INTRODUCTION
Helicobacter pylori, a bacterium found in the stomach of roughly half of the world’s
population, is associated with various gastrointestinal diseases, including peptic ulcers,
non-ulcer dyspepsia, gastric adenocarcinoma, and gastric lymphoma. Although many
infections are asymptomatic, eradication of H. pylori has been shown to reduce the
incidence of gastric cancer and is thus universally recommended[1]. For decades,
clarithromycin-based triple therapy was considered the first-line therapy for H. pylori
eradication and associated gastric cancer prevention. Following the global trend in
emerging antibiotic resistance, rates of clarithromycin, metronidazole, and levofloxacin
resistance among H. pylori strains have increased markedly, causing an alarmingly high
rate of eradication failure[2]. In the absence of universally available antibiotic
susceptibility testing, current guidelines advocate for the use of empiric quadruple
therapy strategies; however, the efficacy of these regimens may be limited by dual
resistance, local availability, and patient adherence[3].
As H. pylori antibiotic resistance rises, the need for new therapeutic strategies
becomes more pressing. Alternative antibiotics, novel acid suppressants, and
vaccination have shown some promise in addressing this challenge[4-7]. Probiotics have
also garnered attention for a possible role in H. pylori treatment, as infection with the
bacterium may be associated with gastric dysbiosis, which can promote inflammation,
metabolic disease, and carcinogenesis[8-12]. With the advent of high throughput 16S
rRNA gene sequencing methods and open-source software for subsequent analysis and
visualization, researchers have been able to characterize changes in the microbial
diversity and community structure of the gut microbiota, as well as specific taxa that
are differentially abundant in association with particular phenotypes[13]. Many studies
have focused on H. pylori-mediated changes to the gastric microbiome, although data
have demonstrated variable patterns of effects on multiple metrics of microbial
diversity and community structure within the gastric microbiome[14]. Given the
challenges associated with obtaining gastric samples, researchers have also focused on
the impact of H. pylori infection on distal gut, i.e., fecal, microbiota, and observed
4
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changes in the fecal microbiome have prompted speculation that such alterations may
be involved in the development of gastrointestinal lesions and cancer[15]. Further
characterization of the interactions between H. pylori and the fecal microbiome, as well
as the mechanisms underlying these interactions, may lead to novel therapeutic
opportunities, as well as to identification of patients at risk for progression to particular
clinical manifestations.
Given the association between H. pylori infection and gastrointestinal inflammation,
attention has also been paid to compounds with anti-inflammatory activity, including
fatty acids. Polyunsaturated fatty acid (PUFA) supplementation in particular may have
therapeutic potential for H. pylori treatment via multiple mechanisms, including
suppression of inflammatory cytokines and enzymes and direct bacteriocidal effects via
disruption of cell membranes[16-18]. 10-hydroxy-cis-12-octadecenoic acid (10-HOE; a
linoleic acid derivative) and docosahexaenoic acid (DHA) have both been shown to
inhibit in vitro growth of H. pylori and gastric infection in mouse models[19,

20].

Nevertheless, the effects of H. pylori infection on fatty acid metabolism in the
gastrointestinal tract are not completely understood. Furthermore, the extent to which
such metabolomic changes may relate to alterations in the gastrointestinal microbiota
are unknown. Notably, short-chain fatty acids (SCFAs) produced by gut microbiota are
thought to play a role in intestinal homeostasis and regulation of immune function, and
dysbiosis in the setting of inflammatory bowel disease (IBD), which is associated with
decreased levels of these important molecules[21, 22]. Exploration of changes in fatty acid
production and metabolism associated with H. pylori-mediated alterations of the fecal
microbiome is warranted, as it may reveal strategies to inhibit the cascade of events
leading to neoplasia.
Previously, we studied the pattern of H. pylori prevalence and antibiotic resistance in
our socioeconomically challenged and underprivileged inner-city community[23]. As a
next step, we then sought to characterize the gut microbiome associated with H. pylori
infection in our patients. We further explored interactions among H. pylori infection, the
gut microbiota, and the gut metabolome by comparing stool fatty acid profiles between
5
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subjects with and without H. pylori infection. Our overarching goal is to identify
potential targets for intervention that could improve H. pylori eradication rates and limit
the consequences of repeated treatment failure.

MATERIALS AND METHODS
Patients and sample collection
Patients presenting to the Cooper Digestive Health Institute in Camden, New Jersey
and diagnosed with H. pylori infection via biopsy were recruited for our study. H. pylori
patients at least 18 years of age and diagnosed via biopsy between June 1, 2017 and
December 31st, 2019, were eligible for inclusion. Patients less than 18 years old,
pregnant women, patients taking antibiotics at the time of recruitment or sampling, and
non-English speaking patients were excluded from participation. Control participants
were recruited from a healthy population, also seen at Cooper Health Institute for well
visits. Informed consent was obtained by one of several IRB-approved team members.
Surveys about demographic information and relevant medical history were collected.
Information on diagnosis, disease features, medication, history of antibiotic use, and
treatment regimen were collected from the electronic medical record. Patients were
asked to provide a stool sample before initiating eradication therapy, and samples were
collected and stored in Stool Nucleic Acid Collection and Preservation Tubes (Cat. No.
45630, 45660, Norgen Biotek Corp., Thorold, Ontario, Canada) prior to freezing at –80
oC

as described previously[23].

16S rRNA gene sequencing
Total genomic bacterial DNA extraction was performed from frozen fecal samples using
the Qiagen DNeasy PowerSoil HTP Kit (Cat. No. 12955-4, Qiagen, Valencia, CA, USA).
Adequate DNA yield was confirmed using NanoDrop spectrophotometry. For high
throughput sequencing, 515F–806R Golay barcodes were used to target the
hypervariable V4 region of the 16S rRNA gene, which is highly conserved and ideal for
gut microbiome analysis. Marker genes in isolated DNA were PCR-amplified using
GoTaq Master Mix (Cat. No. M5133, Promega, Madison, WI, USA) as described in
6
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Caporaso et al.[24] PCR products were cleaned and normalized using the SequalPrepTM
Normalization Plate Kit (Cat. No. A1051001, ThermoFisher, Waltham, MA, USA)
following manufacturer’s instructions. Purification of PCR product amplicons was
performed with the QIAquick PCR Purification Kit (Cat. No. 28104, Qiagen).
Quantification of the PCR amplified library was performed with the InvitrogenTM
Quant-iTTM PicoGreenTM dsDNA Assay Kit (Cat. No. P7589, ThermoFisher). 16S rRNA
gene sequencing was performed on normalized pooled amplicons using the Illumina
MiSeq System using a MiSeq reagent kit v2 (300 cycles; Cat. No. MS-102-2002, Illumina
Inc.). FASTQ files for reads 1 (forward), 2 (reverse), and the index (barcode) read were
generated using the BCL-to-FASTQ file converter bcl2fastq (ver. 2.17.1.14, Illumina,
Inc.). Sequencing of the samples was conducted at the University of Colorado Boulder
BioFrontiers Next-Gen Sequencing core facility.
Sequencing data analysis
Analysis was performed using Python-based packages (Python 3.6.12), QIIME 2 2019.4
(denoising and taxonomy assignment), Quantitative Insights Into Microbial Ecology
(QIIME) 2 2020.11 (statistical testing), and Linear Discriminant Analysis using
LEfSe10[25,

26].

Sequences were de-multiplexed then filtered and clustered into sub-

operational taxonomic units (sOTUs) using QIIME 2

DADA2[27]. A masked

phylogenetic tree was created using MAFFT via QIIME2[28, 29]. Taxonomy was assigned
using a naïve-Bayes classifier based on the latest Greengenes 16S rRNA gene database
available as of August 2019 via the QIIME 2 interface (gg_13_8). Additional Python
packages (SciPy.stats, Scikit-bio) were used for statistical tests on QIIME 2-generated
data. Inter-class comparisons were made based on attributes of our population
including: H. pylori status, gender, age group, race, education, and alcohol use. Alpha
and beta diversity analyses were performed in QIIME 2, rarefied to an even sampling
depth of 22,400[30]. Alpha diversity was assessed by Faith’s phylogenetic diversity,
chao1 index, and observed operational taxonomic units (OTUs). Differences in alpha
diversity between groups were determined by Kruskal-Wallis non-parametric rank test
for categorical variables or by Fisher Z transformation on Spearman rho values for
7
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differences between alpha diversity correlations with numeric data across groups.
Bacterial composition (beta diversity) was analyzed by principal coordinate analyses
(PCoA) of both unweighted and weighted unique fraction metric (UniFrac)
phylogenetic distance matrices[31-34]. Beta diversity was assessed for statistical
significance between groups using Monte Carlo permutations [Adonis and
permutational multivariate analysis of variance (PERMANOVA)], and dispersion of
group samples was assessed using permutational analysis of multivariate dispersions
(PERMDISP)[35,

36].

Comparisons of relative abundances of microbial taxa between

groups were performed using Linear Discriminant Analysis (LDA) Effect Size (LEfSe)
with the Huttenhower et al. online interface[37]. Taxa with an LDA value of 2.0 or greater
and a two-tailed p value ≤ 0.05 with Kruskal-Wallis and pairwise Wilcoxon analyses
were

considered

significantly

enriched.

The

code

is

available

at https://github.com/sterrettJD/H-pylori-microbiome-analysis.
Non-targeted fatty acid analysis
Collected fecal samples were stored at –80 oC until analysis. Sample preparation and
analysis were performed using gas chromatography–mass spectrometry (GC-MS) by
Metabolon, Inc. (Durham, NC, USA). This method (Metabolon TAM112-002) measures
the total content of 30 fatty acids in stool samples after conversion into their
corresponding fatty acid methyl esters (FAMEs). The measured concentrations are
provided in weight corrected μg/g of sample. NQ values were treated as a
concentration of 0.001g/mL.
Briefly, stool samples were homogenized and the suspension was weighed out in a
100 mg aliquot in a test tube. Liquid/liquid extraction was performed to extract fatty
acids and remove the nucleic acid preservative. A 250 μL aliquot of each extract was
transferred to a clean analysis tube. The solvent was removed by evaporation under a
stream of nitrogen. Internal standard solution was added to the dried sample extracts,
quality controls (QCs), and calibration standards. The solvent was again removed by
evaporation under a stream of nitrogen. The dried samples and QCs were subjected to
methylation/transmethylation with methanol/sulfuric acid, resulting in the formation
8
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of the corresponding methyl esters (FAME) of free fatty acids and conjugated fatty
acids. The reaction mixture was neutralized and extracted with hexanes. An aliquot of
the hexanes layer was injected onto a 7890A/5975C GC/MS system (Agilent
Technologies, Santa Clara, CA, USA). Mass spectrometric analysis was performed in the
single ion monitoring (SIM) positive mode with electron ionization. Quantitation was
performed using both linear and quadratic regression analysis generated from fortified
calibration standards prepared immediately prior to each run. Raw data were collected
and processed using Agilent MassHunter GC/MS Acquisition B.07.04.2260 and Agilent
MassHunter Workstation Software Quantitative Analysis for GC/MS B.09.00/ Build
9.0.647.0. Data reduction was performed using Microsoft Office 365 ProPlus Excel. The
metabolomic data set for 19 test and 12 control samples is included in the
Supplementary materials (Full data set H. pylori). Volcano plot data are also included as
Supplementary Tables S1, S2 and S3 (Table S1: Volcano plot data with all Helicobacter
data set, Table S2: Volcano plot data with High Bacteroidetes and Table S3: Volcano plot
data with High Firmicutes).
Procrustes analysis
Multi-dimensional scaling (MDS, using the Python package Scikit-learn) was performed
on Bray-Curtis distance matrices created from both the fecal metabolome and fecal
microbiome datasets (using the Python package SciPy.distance), and a Procrustes test
was performed on the metabolomics and microbiome MDS coordinates. As described
by Peres-Neto and Jackson, a Procrustes randomization test (PROTEST) was performed
by randomly sampling the MDS coordinates and performing a Procrustes test on the
reordered coordinates 10,000 times, and the p value was calculated based on the portion
of randomized Procrustes tests with resulting m2 (Gower’s statistic) scores lower than
the Procrustes m2 score of the observed datasets[38].
Ethics approval
This study received approval by the Cooper Health System Institutional Review Board
(IRB) (17-077EX) and all the steps were carried out as per the standards set by the IRB.
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RESULTS
Fecal microbiome analysis
Selected demographic attributes of our participants are presented in Table 1. Fecal
microbiome analysis of 35 stool samples collected from 19 H. pylori patients and 16
healthy control subjects was carried out. The mean number of reads per sample was
269,462 with a minimum of 22,483 reads/sample. Rarefaction was set to 22,400 for even
sampling based on this minimum.

We analyzed the effect of each of the factors

included in Table 1 on alpha and beta diversity. Age was the only factor that showed
statically significant differences (p value of ≤ 0.05) in the H. pylori patients compared to
the control subjects.
Analysis of alpha diversity
Chao1 index alpha diversity between H. pylori patients and control subjects and
regression analysis of observed OTUs by age are shown in Figure 1. Alpha diversity,
which estimates the diversity of a microbial community within a sample, incorporates
the number of different OTUs and their respective abundance in each sample. Alpha
diversity was lowest in H. pylori patients over 40 years of age, who had significantly
lower Chao1 scores compared to control subjects over 40 years of age (Kruskal-Wallis H
= 6.036, p = 0.014). H. pylori patients over 40 years old also had lower Chao1 scores
approaching statistical significance when compared to H. pylori patients under 40
(Kruskal-Wallis H = 2.813, p = 0.094). Additionally, the correlation of age with observed
OTUs (Figure 1B), Faith's phylogenetic diversity, and Chao1 was consistently different
between H. pylori patients versus control subjects, as evidenced by a Fisher Z
transformation on Spearman rank correlation rho values (observed OTUs: H. pylori rho =
–0.21 vs control rho = 0.50, Fisher p = 0.041; Faith: H. pylori rho = –0.04 vs control rho =
0.57, Fisher p = 0.067; Chao1: H. pylori rho = –0.15 vs control rho = 0.44, Fisher p = 0.097).
Next we analyzed beta diversity of our samples, which estimates how samples differ
from each other. An unweighted UniFrac PCoA plot of H. pylori patients versus control
subjects is shown in Figure 2. Adonis testing revealed that current H. pylori infection
represented 7% of the variation in unweighted UniFrac beta diversity (F = 2.523, R2 =
10
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0.071, p = 0.002). Additionally, unweighted UniFrac PERMANOVAs identified
significant differences between H. pylori patients and control subjects (F = 2.523, p =
0.001). Furthermore, unweighted UniFrac PERMDISP did not reveal differences in
dispersion among H. pylori patients versus control subjects (F = 0.0506, p = 0.809), but
weighted UniFrac PERMDISP did (F = 6.82955, p = 0.017). We also explored the effect of
the use of proton pump inhibitors (PPIs) via beta diversity analysis as PPIs are the
medications commonly given to H. pylori patients and we had previously noted their
influence

on

the

antibiotic

resistance

of

H.

pylori[23].

Unweighted

UniFrac

PERMANOVA identified differences between PPI users and non-users across all
participants (F = 1.939, p = 0.012), though the magnitude of the effect was smaller than
that seen for H. pylori infection as described above. It should also be noted that only
four H. pylori patients and one control subject were on PPI at the time of study and
sample collection, so its contribution to the results described here may not be
significant.
Linear discriminant analysis effect size
LEfSe scores for taxa that were differentially distributed across H. pylori patients versus
control subjects are shown in Figure 3. Thirty-eight taxa had lower relative abundance
in H. pylori patients relative to healthy control subjects, and six taxa had higher relative
abundance in H. pylori patients relative to healthy control subjects. Taxa that were
enriched in H. pylori patients include Atopobium, Gemellaceae, Micrococcaceae,
Gemellales and Rothia (R. mucilaginosa). Figure 4 shows the arcsin square root
transformed relative abundances of each phylum, grouped by H. pylori status. Notably,
relative abundance of the phylum Verrucomicrobia was decreased in H. pylori patients
compared to control subjects.
Procrustes analysis
The Procrustes randomization test was carried out to investigate the relationship
between the fecal microbiome and fecal metabolome. Procrustes analysis identified a
significant relationship between the two datasets, as the resulting p-value of 0.017
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indicates that the correspondence of each participant's fecal microbiome to their fecal
metabolome was better than 98% of randomly sampled simulations (Figure 5).
Fecal Fatty acid analysis
To evaluate the impact of H. pylori infection on fatty acid composition, we performed
non-targeted metabolomics analysis of a panel of 30 fatty acids including long chain
fatty acids (LCFAs), monounsaturated fatty acids (MUFAs) and polyunsaturated fatty
acids (PUFAs). We prepared a volcano plot evaluating changes in fatty acid profile for
the entire population of H. pylori patient samples relative to healthy control subjects
(Figure 6a). In addition, we prepared separate volcano plots for subgroups of the H.
pylori patients with high Bacteroidetes and high Firmicutes based on 16S rRNA gene
analysis (Figure 6b and c). See Supplementary materials (Tables S1, S2, S3) for the full
volcano plot data. Volcano plots allow for the plotting of p-values versus fatty acid fold
change from control samples for all evaluated fatty acids.
Stool samples from H. pylori patients showed increases in several fatty acids including
the PUFAs 22:4n6, 22:5n3, 20:3n6 and 22:2n6 while decreases were noted in fatty acids
including the PUFA 18:3n6, relative to healthy control subjects. The pattern of changes
in fatty acid concentration was correlated to the Bacteroidetes:Firmicutes ratio
(determined by 16S rRNA gene analysis). Among the sub-population identified to have
high Bacteroidetes (Bacteroidetes:Firmicutes ratio ≥ 1 standard deviation above control
ratio, n=7) we found several fatty acids that were diminished from control including the
LCFAs 24:0, 22:0 and 15:0 along with MUFAs 20:1n9 and 18:1n9. By contrast, in the subpopulation identified to have high Firmicutes (Firmicutes:Bacteroidetes ratio ≥ 1
standard deviation above control ratio; n=4) a distinct set of fatty acids were found to be
significantly increased and decreased from controls. In this subpopulation we observed
increases in the PUFA 22:2n6 and decreases in PUFAs 18:3n6 and 20:4n3.
DISCUSSION
Our sample size is modest due to the stringent limitations posed by the socioeconomic
and cultural attributes of our patient population and logistic challenges. Camden
County has the lowest median income and highest poverty and unemployment rates in
12
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southern New Jersey. It also has the lowest educational attainment and the greatest
socioeconomic disparities among ethnic minority groups. More than one third of the
population in Camden City, where our hospital is located, lives below the national
poverty line, and the median household income is USD $26,105[39]. Our local community
is thus considered one of the poorest and most economically distressed communities in
the United States. A significant fraction of adults over 25 years old (almost one quarter)
have not completed high school. It is possible that this influences patients’ appreciation
of the relevance of the study and willingness to participate. Please note that in the
present study, 13 out of 19 participating patients had education level of high school or
less. A significant portion of potential participants were excluded due to non-Englishspeaking status, thus being unable to partake in the informed consent process. Logistic
challenges imposed by the process of stool sample collection also limited the number of
subjects. A large number of potential participants were unable to return to the clinic for
stool sample delivery due to poor transportation access or inability to leave
employment or domestic responsibilities during the window for sample collection (after
diagnosis but prior to initiation of antibiotics). Nonetheless, the present study yielded
meaningful results.
H. pylori infection was associated with significantly decreased fecal microbial
diversity among patients over the age of 40 years, while the control subjects had the
highest microbial diversity. Correlations between age and multiple metrics of microbial
alpha diversity were consistently different between H. pylori patients and control
subjects. H. pylori was also shown to account for a significant portion of the variation in
beta diversity between infected patients and control subjects. Collectively, these results
could suggest an H. pylori-mediated transformation of the fecal microbiome that
progresses with age and becomes apparent by mid-adulthood. Central to this
transformation is a decline in fecal microbial diversity that may be the result of longstanding infection in which H. pylori alters the gastrointestinal environment at the
expense of other taxa. This conclusion is consistent with those of other studies that
attributed decreased diversity of gastric microbiota to the ability of H. pylori to
13
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outcompete other species[9,

14, 40].

Secretion of antibacterial peptides and local pH

alterations have been proposed as mechanisms that may account for the alteration of
the gastric microbiota diversity and community structure by H. pylori[41]. The impact of
H. pylori on fecal microbial diversity observed in our study may be reversible, just as a
recent study showed that H. pylori eradication could restore gastric microbial diversity
to levels seen in uninfected controls[42].
Conversely, the data may reflect a preceding decrease in gut microbial diversity that
facilitates H. pylori infection, possibly mediated by other factors or exposures that
accumulate with age. In other words, patients who experience decreased gut microbial
diversity as they age, potentially mediated by diet or chronic inflammation, may be
more prone to H. pylori infection, particularly by mid-adulthood. In our previous study
of 2,014 H pylori patients, we observed that 80% of our patients were above the age of 40
years[23]. Antibiotic exposure is known to alter the gut microbiome, and increased rates
of antibiotic resistant-H. pylori among older adults have been attributed to increased
antibiotic use compared to younger patients[2,

43, 44].

Conceivably, decreased gut

microbial diversity induced by cumulative antibiotic exposure could create an
intragastric niche for H. pylori, and antibiotic resistant H. pylori strains in particular, to
thrive.
LEfSe showed that multiple taxa were differentially enriched or depleted in stool
from H. pylori patients compared to controls. The significance of differential expression
of these taxa is unknown; however, certain taxa stand out. The enrichment of Atopobium
is notable in the context of a metagenomic analysis which revealed increased Atopobium
parvulum abundance among patients with colorectal intramucosal carcinomas[45].
Although H. pylori is predominantly associated with gastric cancers, a recent metaanalysis suggested a significantly increased risk of colorectal cancer as well, and our
data suggest that H. pylori-associated increases in Atopobium abundance may have a role
in the distal gut carcinogenesis[46].
Over-representation of Rothia mucilaginosa, a commensal oral microbe, has
previously been observed in fecal samples from patients with primary sclerosing
14
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cholangitis (PSC)[47]. Because of the sensitivity of R. mucilaginosa to gastric fluid, Bajer et
al. hypothesized that its presence in PSC patients represented contamination of the
intestine via previous endoscopic retrograde cholangiopancreatography[47]. The
enrichment of Rothia sp. in fecal samples from our H. pylori patients may reflect the
potent gastric acid suppression by H. pylori, allowing translocation of swallowed oral
flora to the distal gut. The clinical consequences of the colonization of the distal gut by
Rothia sp. are unknown, although the bacteria has been implicated as a cause of myriad
syndromes, including dental caries, pneumonia, and bacteremia, particularly in
immunocompromised patients[48]. The increased abundance of Gemellaceae in H. pylori
patients is consistent with the observation of increased organisms from the Gemella
genus in patients with current H. pylori infection reported by Gao et al[49]. Microbial
shift that included the expansion of Gemellaceae in the Crohn ileum has been reported
by other groups[50, 51].
Interestingly, the phylum Verrucomicrobia was significantly depleted in H. pylori
patients.

Verrucomicrobia

includes

Akkermansia

muciniphila,

a

mucus-residing

commensal bacterium of the large intestine. A. muciniphila is an obligate
chemoorganotroph, utilizing mucus as a sole carbon, nitrogen, and energy source that
produces SCFAs including acetate, propionate, and, to a smaller extent, 1,2propanediol[52,

53].

Decreased relative abundance of Verrucomicrobia may suggest

disruption of the gut mucosal environment by H. pylori. In a mouse stress model,
exposure to chronic psychosocial stress resulted in expansion of Helicobacter spp., which
has been demonstrated to proliferate in response to glucocorticoid administration as
well as psychosocial stress exposure[54]. Specifically, stress-induced increases in
Helicobacter spp. were associated with increases in other Proteobacteria spp., including
unidentified genera belonging to the Enterobacteraceae and Desulfovibrionaceae
families. Concurrently, relative abundance of Mucispirillum, an obligate mucus-residing
bacterium, decreased; a decline of Mucispirillum in rodents is associated with early
disruption of the gastrointestinal surface mucus layer and a prolonged delay to
recovery after the period of pathogen clearance[55]. Evidence of disruption of the gut
15
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mucosa by H. pylori infection is also consistent with decreased relative abundance of
Faecalibacterium prausnitzii. F. prausnitzii is an important gram-positive human
commensal that produces butyrate and other SCFA through the fermentation of dietary
fiber. Reduced relative abundance of F. prausnitzii has been associated with
inflammatory conditions including Crohn’s disease, obesity, asthma, and stress-related
psychiatric disorders in which inflammation is a risk factor, such as major depressive
disorder[56-59].
The gastric microbiome differs significantly from those of other sites along the
gastrointestinal tract[60]. Nevertheless, H. pylori infection is thought to indirectly alter
distal gut microbial community structure[61]. Recent studies have identified significant
differences in bacterial communities obtained from human duodenal and stool samples
associated with H. pylori infection

[62, 63].

Schulz et al. identified a few phylotypes that

were detected at significantly different rates in duodenal aspirates or biopsies of H.
pylori-positive individuals compared to controls, and this finding may be related to H.
pylori’s association with duodenal ulcers[62]. In contrast to our study, Dash et al.
observed increased alpha diversity among stool samples from H. pylori-positive
individuals, although they found no effect on beta diversity[63]. Finally, Frost et al. found
significant changes in fecal microbiome diversity and composition as measured by
alpha and beta diversity, respectively, in H. pylori positive individuals compared to
controls, and the latter association was strongly correlated with H. pylori stool antigen
load[64]. Differences in the study populations, including geographic, cultural, and
dietary differences, may account for these conflicting findings regarding H. pylori’s
effects on the distal gut microbiome, as these factors are known to significantly impact
fecal microbiome composition[65]. Moreover, methodological differences in analyses of
alpha and beta diversity and relative taxonomic abundance further inhibit comparison
of study results. Nevertheless, our results add to the growing evidence suggesting that
H. pylori is associated with alterations in distal gut microbiota, particularly in those over
40 years of age.
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Strategies to promote increased gut microbial diversity among patients with H.
pylori infection, particularly those over 40 years of age, may hold therapeutic potential
in eradicating infection, and some clinical trials with adjunctive probiotic formulas have
shown promising results in this regard[66]. Likewise, treatment of gut dysbiosis in
patients with H. pylori infection may limit its associated pathologies. Reduced fecal
microbiome diversity is associated with multiple disease markers including increased
adiposity, insulin resistance, dyslipidemia, and a pro-inflammatory state

[67].

H. pylori

infection is associated with higher rates of diabetes, specifically, and addressing gut
dysbiosis in such patients could conceivably aid primary dietary and pharmacologic
strategies to achieve glycemic control and insulin sensitivity[12]. Rehabilitation of the gut
microbiota in patients with H. pylori may also have a role in minimizing the risk of
malignancy. Mouse studies suggest that the carcinogenic effects of H. pylori partly
depend on interactions with the gut microbiome, and persistent infection with H. pylori
may create a niche favorable for taxa that are found in increased abundance in gastric
cancer, including Lactobacillus and Lachnospiraceae[9,

68, 69].

It has been suggested that

lactic acid bacteria can influence gastric cancer by a number of mechanisms such as (i)
supply of exogenous lactate, that acts as a fuel source for cancer cells, (ii) production of
reactive oxygen species and N-nitroso compounds and (iii) by allowing colonization of
carcinogenic non-H. pylori bacteria[70]. Accordingly, reversal of abnormalities in gut
microbiota associated with H. pylori may also limit its carcinogenic potential. Finally,
consideration must be given to the effects of H. pylori treatment on the gut microbiome,
as data suggest that current therapies may be associated with dysbiosis and subsequent
adverse effects[71].
While evaluating changes in the long-chain fatty acids (LCFAs) palmitic (16:0) and
stearic (18:0) concentrations, we found that palmitic acid concentrations were increased
in our test samples compared to control samples (625.23േ598.82 g/g (n=18) versus
334.10േ284.58 g/g (n=12)), whereas concentrations of stearic acid were comparable
between populations. Interestingly, when we evaluated the high Firmicutes (>1.4:1
Firmicutes: Bacteroidetes, n=4) sub-group compared to the high Bacteroidetes (>2.7:1
17
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Bacteroidetes: Firmicutes, n=7) sub-group of our test population we found the
concentrations of both these LCFAs to be diminished in the high Bacteroidetes
population while the concentrations of both were enhanced in the high Firmicutes subpopulation. This is consistent with previous studies in mice where administration of
LCFA-rich diets resulted in an observed increase in Firmicutes to Bacteroidetes ratio[72].
Ktsoyan et al. implicated a characteristic profile of serum LCFA concentrations in
association with H. pylori infection compared to healthy controls[73]. It is plausible that
diet can modulate the impact of H. pylori on the gut microbiome, which in turn may
relate to different disease phenotypes, i.e., asymptomatic infection, peptic ulcer disease,
and gastric cancer.
The accumulation of the saturated LCFAs is regulated under normal physiological
conditions by desaturation of 16:0 to 16:1n7, elongation of 16:0 to 18:0 and/or
desaturation of 18:0 to 18:1n9 which can be further elongated to 20:1n9 (Figure 7). While
only small changes in concentrations of these MUFAs were noted between our H. pylori
patients and control subjects, the changes in MUFA concentrations in our high
Firmicutes and high Bacteroidetes sub-populations showed more significant and
consistent changes across the series of MUFAs. The concentration of 16:1n7, 18:1n9 and
20:1n9 were decreased in the high Bacteroidetes sub-group, whereas these MUFAs were
slightly increased in the high Firmicutes sub-group. Interestingly, this contrasts
published data on the benefits of high MUFA diets in animal models and humans. In
previous studies, high MUFA diets have been reported to lead to increased ratios of
Bacteroidetes to Firmicutes and were correlated with reductions in several disease
indicators[72]. Together, these observations may suggest that either the patients in our
high Bacteroidetes sub-population have severely limited MUFA production/intake,
contrasting previous work on MUFA rich diets or that the endogenous biosynthetic
pathways for MUFA production are dysregulated in this patient population.
The range of PUFAs observed endogenously have essential physiological roles and
are produced from dietary alpha-linolenic acid (18:3n3) and linoleic acid (18:2n6). We
observed that both of these dietary PUFAs were increased in our test samples compared
18
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to the control samples. In humans, C18:2n6 is converted through multiple steps to
eicosapentaenoic acid (EPA, 20:5n3) and docosahexaenoic acid (DHA, 22:6n3), whereas
18:3n3 proceeds to produce arachidonic acid (AA, 20:4n6) (Figure 7). As these two
biosynthetic pathways share enzymes for their respective dehydration and elongation
steps, they are antagonistic to each other. In general, a high 18:3n3 (n-3 fatty acid) diet is
correlated with positive physiological effects whereas a high 18:2n6 (n-6 fatty acid) diet
is correlated with metabolic dysbiosis and negative physiological effects[74,

75].

Accordingly a balanced dietary intake of n-6/n-3 fatty acids is recommended to be 1:12:1, although the average ratio in a typical Western diet has been reported to be >15:1[76].
In accordance with published ratios for n-6/n-3 fatty acid intake in Western diets, we
find the ratio of 18:2n6/18:3n3 to be 22:1 in our control samples and 15:1 in our H. pylori
patient test samples.
Endogenously, the essential dietary fatty acid 18:3n3 undergoes multiple
dehydration and elongation steps to produce docosapentaenoic acid (DPA, 22:5n3) and
docosahexaenoic acid (DHA, 22:6n3). For all intermediates along this biosynthetic
pathway, with exception to 18:3n3 and 22:5n3, we observe concentrations at or below
the limit of quantification for the majority of samples making an evaluation of the
individual steps of this biosynthesis pathway difficult.
Contrasting the low concentrations observed for 18:3n3 and fatty acids produced
along this biosynthetic pathway, higher overall concentrations were observed for fatty
acids derived from 18:2n6, perhaps reflecting the higher concentration of dietary n-6
fatty acids as described earlier. In humans, the dietary fatty acid, 18:2n6 undergoes
dehydration to produce 18:3n6. This intermediate undergoes a subsequent elongation to
produce 20:3n6, which is dehydrated to 20:4n6 (arachidonic acid). Alternatively, 18:2n6
can undergo elongation first to produce 20:2n6, which is dehydrated to produce 20:3n6
(Figure 7).
We found that the early steps in the metabolism of 18:2n6 were significantly
impacted in all of our H. pylori samples by comparison of downstream fatty acid
metabolites to controls. Most notably, in all H. pylori test samples the concentration of
19
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18:3n6 was significantly diminished. Concentration of 18:3n6 was 10.7േ18.2 g/g (n=12)
in the control samples and 0.36േ1.50 g/g (n=18) in the test samples. While we would
anticipate that this deficiency in dehydration of 18:2n6 would lead to lower levels of
fatty acid metabolites downstream of 18:3n6, this is not the case. In fact, by the
following biosynthetic step, i.e., elongation to produce 20:3n6, the fatty acid
concentration of 20:3n6 in test samples was found to be higher than in controls. These
higher concentrations were also reflected in arachidonic acid (20:4n6) and adrenic acid
(22:4n6). It is plausible that the alternative -8-desaturase mediated route via 20:2n6 may
be prominent in these H. pylori patient samples, which are marked by a deficiency in 6-desaturase mediated pathway via 18:3n6[77].
As the burden of antibiotic resistance grows, populations like ours are impacted
greatly by the high prevalence of H. pylori colonization. As eradication by a one-fits-all
approach becomes more and more difficult, it becomes even more important to look
towards strategies that can provide insight into community attributes that can help
guide targeted therapies, predict likelihood of treatment outcomes, and possibly create
strategies towards mitigating the impact of increased antibiotic usage. A greater, more
individualized understanding of gut microbiome features among patients experiencing
H. pylori colonization, especially in our underserved population, will pave the way for
better community impact and reduce healthcare burdens of repeated treatment and
mounting resistance. As gut dysbiosis is inextricably tied not only to H. pylori infection
but also to the use of antibiotics itself, the cycle of treatment and re-treatment may very
well only further exacerbate vulnerability to enteric pathogens. Strategies to better
understand gut dysbiosis features among affected groups may create opportunities for
targeted therapy, as well as a potential for creating predictive models for antibiotic
selection, and even exploring restorative probiotic therapy to help lessen the adverse
impact of eradication therapy.
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Table 1. Patient Demographics and Clinical Characteristics
Total (n = 35)
H. pylori patients (n = 19)
Sex
Male
19 (54%)
13 (68%)
Female
16 (46%)
6 (32%)
Age
Ages 18-40
15 (43%)
3 (16%)
Age >40
20 (57%)
16 (84%)
Highest education
Less
than 2 (6%)
2 (11%)
high school
High school 12 (34%)
11 (58%)
Undergradu 4 (11%)
2 (11%)
ate
Graduate
15 (43%)
3 (16%)
Post1 (3%)
0 (0%)
graduate
Race
African
8 (23%)
6 (32%)
American
Asian
2 (6%)
0 (0%)
American
Caucasian
13 (37%)
1 (5%)
Non-White
8 (23%)
8 (42%)
Hispanic
Other
3 (9%)
3 (16%)
Smoker
5 (14%)
4 (21%)
1 (5%)
Past
H.
pylori 1 (3%)
treatment
Duodenal ulcer
1 (3%)
1 (5%)
Non-ulcer
14 (40%)
10 (53%)
dyspepsia
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Control (n = 16)
6 (38%)
10 (62%)
12 (75%)
4 (25%)
0 (0%)
1 (6%)
2 (13%)
12 (75%)
1 (6%)

2 (12%)
2 (12%)
12 (75%)
0 (0%)
0 (0%)
1 (6%)
0 (0%)
0 (0%)
4 (25%)
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Figure 1. Chao1 index alph
ha diversitty and ob
bserved OT
TUs by H
H. pylori sttatus
stratified by age. A:
A Chao1 in
ndex alpha diversity
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is compared between H
H. pylori pattients
(blue) an
nd control subjects
s
(orrange), subgrouped by
y age. H. pyylori patients over 40 y
years
old (n=1
16) had sig
gnificantly lower
l
Chao
o1 scores ccompared tto control ssubjects oveer 40
(n=4) (K
Kruskal-Wa
allis H = 6.0
036, p = 0.0
014). Boxes represent 1st and 3rd
d quartiles,, and
central lines
l
repreesent media
an values. Whiskers represent n
non-outlierr high and low
values. Points
P
show
w outliers, which were determin
ned by haviing a distan
nce from th
he 1st
or 3rd quartile grreater than
n 1.5 timess the interrquartile raange. B: O
Observed O
OTUs
(operatio
onal taxono
omic units)) are compa
ared betweeen H. pylorii patients (b
blue, n=19)) and
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s
(orrange, n=16
6), as a funcction of age . Shading aaround the regression lines
indicates 95% confiidence interrvals.
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Figure 2.
2 Beta dive
ersity analy
ysis by unw
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UniFrac PCoA. Unweiighted Prin
ncipal
Coordin
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wn comparring H. pyloori patientss (blue, n=119) to
control subjects (rred, n=16). Significan
nt differencces betweeen H. pylorri patients and
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s
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RMANOVA
A (F = 2.5233, p =
0.001). The
T
propo
ortion of variance
v
ex
xplained by
y each priincipal coo
ordinate ax
xis is
denoted
d in the corrresponding
g axis labeel; PCo1 exxplains 16.995% of the variability
y and
PCo2 ex
xplains 9.13% of the va
ariability.
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Figure 3.
3 Linear discriminan
d
nt analysis effect sizee (LEfSe). L
LEfSe scores for taxa that
were differentially
y distributeed across H.
H pylori paatients (n=119) versus ccontrol sub
bjects
(n=16) via
v Kruskal--Wallis and
d Wilcoxon
n tests with two-tailed α = 0.05. N
Negative vaalues
represen
nt taxa tha
at were en
nriched in
n H. pylori patients, whereas p
positive vaalues
represen
nt taxa tha
at were en
nriched in control su
ubjects. Errror bars reepresent a 95%
confiden
nce intervall and are on
nly presentt if the listeed taxonom
mic identity was the lo
owest
level cla
assified for multiple
m
OT
TUs highlig
ghted by LE
EfSe. Colorr representss the phylum
m.
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Figure 4.
4 Relative
e phylogen
nic abunda
ance. Arcsiin square root transfformed relative
abundan
nces of each
h phylum, grouped by H. pylori status. Baccterial relative abundaances
of H. py
ylori patien
nts (n=19) are
a shown
n in blue, w
whereas heealthy conttrols (n=16)) are
shown in
i orange. Boxes reprresent the 1st
1 and 3rd
d quartiles, and vertiical lines in
n the
middle of the box
xes represeent median
n values. W
Whiskers rrepresent tthe lowest and
highest non-outlierr values. Points show
w outliers, w
which weree determined by haviing a
distancee from the 1st or 3rd quartile greater than 1.5 times tthe interquartile rangee. Of
note, reelative abun
ndances off Verrucom
microbia w
were significcantly low
wer in H. ppylori
patients compared to healthy controls (K
Kruskal-Waallis H = 4.4455, p = 0.0334).

25

bioRxiv preprint doi: https://doi.org/10.1101/2021.05.23.445270; this version posted May 25, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 5.
5 Procruste
es analysis
Connecttions betweeen the feccal microbiiome and fecal metab
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MDS
plots. The
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d lines havee been draw
wn to
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m
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participants. Orange dots
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nt the micrrobiomes, whereas blue trianglles represen
nt the mettabolomes. The
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nt relationsship betweeen the datasets
(m2 = 0.8
86, p = 0.017
7).
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Figure 6.
6 Volcano plots of co
omposition
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ontrol versu
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nts identifieed as
having high
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Figure 7. Major metabolic pathways. Selected long-chain fatty acids (LCFAs, no fill),
monounsaturated fatty acids (MUFAs, light grey fill) and polyunsaturated fatty acids
(PUFAs, dark grey fill) are highlighted. Although many of the fatty acids shown may be
supplemented by diet, key parent members of these pathways acquired from de novo
lipogenesis (DNL) and/or diet are indicated.
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